Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $192.00 at HC Wainwright

Neurocrine Biosciences (NASDAQ:NBIX) had its target price dropped by HC Wainwright from $198.00 to $192.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 39.70% from the company’s previous close.

A number of other research firms also recently weighed in on NBIX. Canaccord Genuity Group boosted their target price on Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Stifel Nicolaus boosted their price objective on shares of Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Zacks Research cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. JPMorgan Chase & Co. decreased their target price on shares of Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating on the stock in a research report on Monday, January 12th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Thursday, January 22nd. Fifteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $175.72.

Neurocrine Biosciences Stock Down 0.2%

NASDAQ NBIX opened at $137.44 on Thursday. The stock’s 50-day simple moving average is $141.39 and its two-hundred day simple moving average is $140.58. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $160.18. The company has a market capitalization of $13.70 billion, a price-to-earnings ratio of 32.88, a PEG ratio of 0.65 and a beta of 0.31.

Insider Activity

In related news, Director Leslie V. Norwalk sold 1,190 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total value of $184,557.10. Following the sale, the director directly owned 6,239 shares of the company’s stock, valued at $967,606.51. This trade represents a 16.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Darin Lippoldt sold 4,376 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $159.65, for a total value of $698,628.40. Following the transaction, the insider owned 43,405 shares in the company, valued at approximately $6,929,608.25. This represents a 9.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 61,966 shares of company stock valued at $8,625,166. Company insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently bought and sold shares of the business. USA Financial Formulas bought a new position in Neurocrine Biosciences in the 4th quarter worth about $25,000. Geneos Wealth Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. Golden State Wealth Management LLC boosted its position in Neurocrine Biosciences by 120.5% in the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after purchasing an additional 100 shares during the last quarter. Eastern Bank bought a new position in shares of Neurocrine Biosciences in the 3rd quarter worth approximately $27,000. Finally, Quent Capital LLC bought a new stake in Neurocrine Biosciences during the third quarter valued at approximately $32,000. Institutional investors own 92.59% of the company’s stock.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Management highlighted strong sales growth and durable commercial momentum (INGREZZA) in the Q4 presentation, supporting longer‑term franchise confidence. Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and …
• Positive Sentiment: Analysts remain constructive: Needham kept a Buy and nudged its price target to $185, citing durable Ingrezza growth and an emerging Crenessity ramp despite near‑term cost pressure. Neurocrine Biosciences: Durable Ingrezza Growth and Emerging Crenessity Ramp Support Buy Rating Despite Near-Term Cost Pressures
• Positive Sentiment: TD Cowen and other buyside/agency analysts reiterated Buy ratings, underscoring confidence in franchise momentum and pipeline investments. Neurocrine Biosciences: Durable Franchise Momentum and Pipeline Investment Support Buy Rating
• Neutral Sentiment: The company posted its full PR with product sales and 2026 expectations; Ingrezza full‑year 2026 net product sales guidance was set at $2.7–$2.8 billion (management framed 2026 as a year of investment). Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
• Neutral Sentiment: Full earnings‑call transcript is available for details on pipeline progress, cost items and management commentary that traders will parse for 2026 cadence. Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: EPS missed consensus: reported $1.88 vs. street estimates near $2.25–$2.36 (different sources); the bottom‑line shortfall is the main catalyst for the near‑term share weakness. Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
• Negative Sentiment: Market reaction: shares dipped after the print; coverage pieces note the stock fall and flag extensive insider selling activity in recent months — a potential sentiment headwind. Neurocrine Biosciences Inc. (NBIX) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Some outlets characterize the company’s 2026 guidance as cautious, reflecting investments and cost pressure that could compress near‑term margins. Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.